<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Grifols Therapeutics Inc.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biological Classification</td>
<td>Passive: Immune Globulin</td>
</tr>
</tbody>
</table>
| Indications for Provincially Funded Vaccine | Measles: Post-exposure:  

Hepatitis A: Post-exposure:  
| Preferred Use | N/A |
| Dose | Measles Post-exposure:  
- 0.25 mL/kg of body weight (maximum 15 mL)  
- 0.5 mL/kg of body weight (maximum 15 mL) if individuals are immunocompromised or have underlying malignant disease  

Hepatitis A post-exposure:  
- 0.1 mL/kg of body weight  

Note: Doses may need to be divided and injected into several muscle sites to reduce local pain and discomfort. |
| Route | IM |
| Schedule | Measles contacts:  
- IG can be given up to and including 6 days after exposure to prevent or modify measles; preferably within 3 days.  

Hepatitis A contacts:  
| Contraindications/Precautions | Contraindications:  
- Known severe hypersensitivity to any component of the biological  
- Anaphylactic or other allergic reactions to a previous dose of biological containing human immune globulin preparations |
GamaSTAN® S/D

- Should not be given to individuals with IgA deficiencies. These individuals have the potential to develop anti-IgA antibodies and could have anaphylactic reactions to subsequent administration of blood products containing IgA.

Precautions:
- Individuals with thrombocytopenia or coagulation disorders that contraindicate IM injections should not be given IM immune globulin unless the expected benefits outweigh the risks.
- Use with caution in clients with a history of prior systemic allergic reactions following administration of human immunoglobulin preparations.
- Do not administer intravenously because of the potential for serious reactions.
- Human IG preparations are among the safest blood-derived products available.
- GamaSTAN® S/D is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses, that can cause disease. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, testing for the presence of certain current viral infections and inactivating and/or removing certain viruses. Despite these measures, such products can still potentially transmit disease.
  - A signed Consent for Treatment/Procedure is required before administering immune globulin products:

### Possible Reactions

**Common:**
- Local pain and tenderness at the injection site
- Urticaria and angioedema may occur

**Rare:**
- Anaphylactic, allergic reactions
- There is clinical evidence of an association between the administration of all immunoglobulins and thromboembolic events such as myocardial infarction, stroke, pulmonary embolism and deep vein thrombosis.
- As with any immunization, unexpected or unusual side effects can occur. Refer to the product monograph for more detailed information.

### Pregnancy

- Use only if the benefit outweighs the potential risk.
- Intact IgG crosses the placenta from maternal circulation increasingly after 30 weeks gestation.

### Lactation

Can be administered to eligible breastfeeding women.

### Composition

- 15%-18% immune globulin at pH of 6.4 to 7.2
- 0.21 to 0.32 M glycine
- pH adjusted using sodium carbonate

Contains no preservative

### Blood/Blood Products

Prepared by cold ethanol fractionation from human plasma.

### Bovine/Porcine Products

- One material used in the early manufacturing process is of bovine origin, but this material is not present in the final product.
- Contains no porcine products.

### Latex

Present in all stoppers, seals and closures

### Interchangeability

N/A
GamaSTAN® S/D

Administration with Other Products

- The recommended interval between IG administered IM and subsequent immunization with live vaccine (i.e., varicella, MMR or MMR-Var) varies from 3 to 6 months, depending on the dosage of IG given. IG cannot be given concurrently with live virus vaccines.
- When it is necessary for IG to be administered IM less than 14 days after receiving MMR, MMR-Var or varicella vaccine, the immunization with MMR, MMR-Var or varicella should be repeated.
- The concurrent administration of hepatitis A vaccine and human IG does not influence the seroconversion rate. Hepatitis A vaccine and IG should be administered using separate needles/syringes and at different injection sites.

Note:
- For further information, see #03.110 Standard for Recommended Immunization Schedules.

Appearance
Clear, colourless solution, slightly opalescent, viscous

Storage
- Store between +2° and +8°C
- Do not freeze
- Do not use beyond the labeled expiry date
- Store in original packaging when possible to protect from light

Vaccine Code
IG

Antigen Code
IG

Licensed for
Persons of all ages

Notes:
- Use a blunt fill or large bore needle to withdraw immune globulin. Withdrawal through a small-gauge needle can lead to aggregation.
- Inject slowly
- IG is supplied in 2 mL, 5 mL and 10 mL single use vials.

Related Documents:
- Immune Globulin Information Sheet for the Prevention of Hepatitis A
- Immune Globulin Information Sheet for the Prevention of Measles

References: